[
  {
    "overallHR": {
      "lowerCI": 0,
      "upperCI": 0,
      "title": "Overall",
      "hazardRatio": 0
    },
    "id": 27,
    "title": "",
    "combinations": [
      3
    ],
    "description": "",
    "infoPSA": "≥50% decline in PSA level from baseline",
    "drugCombinations": [
      {
        "condition": 0,
        "subTitle": "",
        "dataPSA": [
          {
            "title": "Lu-PSMA-617",
            "psaResponseRate": "66",
            "timeToPSAProgression": "Not Reported",
            "objectiveDiseaseProgression": ""
          },
          {
            "title": "Cabazitaxel",
            "psaResponseRate": "37",
            "timeToPSAProgression": "Not Reported",
            "objectiveDiseaseProgression": ""
          }
        ],
        "figures": [
          {
            "value": 0,
            "caption": "RADIOGRAPHIC PROGRESSION FREE SURVIVAL (rPFS)",
            "image": "TheraP_rpfs",
            "description": ""
          },
          {
            "value": 0,
            "caption": "OVERALL SURVIVAL (OS)",
            "image": "TheraP_os",
            "description": ""
          }
        ]
      }
    ],
    "hazardRatioTitle": "",
    "hazardRatios": [],
    "note": "",
    "references": "Bolhuis, M.S. et al. (2024) “Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial,” The Lancet Oncology, available: https://doi.org/10.1016/s1470-2045(23)00529-6\n\nMargonics, M.S. et al. (2021) “[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial,” The Lancet, available: https://doi.org/10.1016/s0140-6736(21)00237-3\n\nFong, M.S. et al. (2021) “[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial,” The Lancet, available: https://doi.org/10.1016/s0140-6736(21)00237-3"
  }
]